Indication
Unknown primary tumor
6 clinical trials
5 products
3 drugs
Product
MCLA-128Clinical trial
Treatment Plan of the HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid TumorStatus:
Product
Systemic TreatmentClinical trial
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)Status: Recruiting, Estimated PCD: 2029-10-01
Clinical trial
A Phase II, Randomized, Multicenter Study to Assess the Efficacy of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP): The AGNOSTOS TrialStatus: Completed, Estimated PCD: 2021-05-04
Drug
AbraxaneProduct
CarboplatinDrug
GemcitabineClinical trial
Therapeutic HPV Vaccine (BNT113) Trial in HPV16 Driven CarcinomaStatus: Completed, Estimated PCD: 2023-11-01
Product
BNT113Clinical trial
Canadian Atezolizumab Precision Targeting for Immunotherapy InterventionStatus: Recruiting, Estimated PCD: 2026-10-01
Drug
AtezolizumabClinical trial
A Phase II, Non-Randomized, Open-Label, Single-center, Physician Sponsored Study to Determine the Safety and Effectiveness of Lu-177 DOTATOC in Adult Subjects With Somatostatin Receptor Expressing Pulmonary, Pheochromocytoma, paragangliomUnknown Primary, and Thymus Neuroendocrine Tumors (PUTNET) or Any Other Non-.GEP-NET.Status: Withdrawn, Estimated PCD: 2021-07-15
Product
177Lu-DOTATOC